-
Major progress has been made in the treatment of coronary heart disease in the UK, according to a report issued by Health Secretary John Reid. The report, Winning the War on Heart Disease, said that deaths from cardiovascular disease in the UK fell by more than 23% between the periods 1995-97 and 2000-02.
-
A story in the January issue of CDU included an incorrect reference to the InRatio point-of-care tester for prothrombin time as being an i-STAT (East Windsor, New Jersey) product. InRatio is manufactured by HemoSense (Milpitas, California).
-
In a move designed to shore up its sagging vascular brachytherapy (VBT) sales, which have been ravaged by the drug-eluting stent (DES) phenomenon, Novoste (Norcross, Georgia) said in an earnings conference call last month that it had signed an agreement with Guidant (Indianapolis, Indiana) to facilitate a transition to Novoste products by existing customers of Guidants vascular brachytherapy system in the U.S. and Canada.
-
Bypass surgery done on a beating heart is just as effective as the conventional operation performed with a heart-lung machine, and less expensive, according to a study reported last month.
-
A consensus group making recommendations on the use of restraining therapies in the ICU emphasizes the inadequacy of the evidence base in this area and calls for studies to generate better data.
-
This single-center study reveals that, compared to continuous sedation, daily sedative interruption is not associated with adverse psychological effects after 6-21 months.
-
Adult patients presenting with acute asthma without significant respiratory acidosis who were given 100% oxygen to breathe had slight increases in arterial PCO2 and slight decreases in arterial pH and peak expiratory flow, as compared with patients who received only 28% oxygen.
-
In late-onset VAP, survival improved and costs decreased using initial coverage with 3 antibiotics. Mini-BAL did not improve survival but decreased costs and antibiotic usage.
-
-
